As Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is...
Maggie Fick And Patrick WingroveLONDON/NEW YORK - As Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my patients actually get at the pharmacy?
"The reality we live in right now is that we are beholden to these supply issues," said Dr. Eduardo Grunvald, an obesity medicine physician at University of California, San Diego. “While we will do our best to support those who want to start taking Wegovy, it is important to recognize that overall demand will continue to exceed supply and some patients may still have difficulty filling Wegovy prescriptions,” Novo said in an update on its website.
Both companies have announced plans to spend billions of dollars to boost manufacturing by expanding factories, building or buying new ones and seeking more deals with contract drug manufacturers. Since the beginning of this year's second quarter, the Danish drugmaker has filled an average of nearly 170,000 U.S. Wegovy prescriptions per week. Indianapolis-based Lilly has filled an average of just under 100,000, according to weeks of IQVIA data reported by analysts.
The market landscape also would change if companies can introduce more effective or convenient versions of these weight-loss drugs, such as a pill that works as well as injections, they said.
Weight Loss Obesity Obese California Canada Canadian Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies Single-Blind Study Single-Blind Studies Drug Shortages Medication Shortages Germany German Hands Healthcare And Medical Technology Health And Medical Tech Health And Med Tech
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatmentsQuestions about whether Eli Lilly and Novo Nordisk can maintain their duopoly in weight loss drugs are fair game, but come 'too soon,' one analyst said.
Read more »
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from RocheNovo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche’s latest obesity drug candidate.
Read more »
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from RocheNovo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate.
Read more »
Novo Nordisk stock price falls after Eli Lilly weight loss drug outperforms OzempicPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »
Intel, Nvidia, Eli Lilly rise premarket; BP, Novo Nordisk fallIntel, Nvidia, Eli Lilly rise premarket; BP, Novo Nordisk fall
Read more »
Novo Nordisk's Wegovy wins EU backing for reducing heart risksNovo Nordisk's Wegovy has received backing from the EU's medical regulator to expand the weight loss drug's use to reducing the rise of serious heart events.
Read more »